ArticleScience (New York, N.Y.)2018
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
7 registry-linked trialsAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 3,443 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3,443citing papers in PubMed, 5 pooled it
175.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Biomarkers For Immune Checkpoint Inhibitors
Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.
NCT05620004 phase1 / phase2unknown statusnot on this mapstarted 2021, after this paper: background citation
Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy: a Randomized Controlled, Single-center Clinical Trial
Mediterranean Diet and Inequality in Early Breast Cancer: A Multicenter Randomized Clinical Trial
Who cites it
3,443 citing papers in PubMed, 5 syntheses or guidelines pooled it, 5,249 citations in OpenAlex.
- The gut microbiota-obesity axis in the pathogenesis and prognosis of breast cancer.Annals of medicine · 2026Pooled it
- Preclinical Evaluation of Bacterial Lysates in Murine Disease Models: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- Heating the Cold: Overcoming Immunotherapy Resistance in Microsatellite-Stable Colorectal Cancer: A Systematic Review.Molecules (Basel, Switzerland) · 2026Pooled it
- The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment.Prostate cancer and prostatic diseases · 2026Pooled it
- Faecalibacterium prausnitzii and Akkermansia muciniphila: driving the multiple sclerosis-a systematic review.Antonie van Leeuwenhoek · 2026Pooled it
- Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.Journal for immunotherapy of cancer · 2026Trial
- Axitinib plus Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma: Biomarker Analysis and Updated Results of the Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Trial
- Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.Nature communications · 2026Trial
- Host diets drive microbiome evolution and functional divergence.Genes & diseases · 2027Review
- The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future.Gut microbes · 2026Review
- Modulation of the response to immunotherapy in triple-negative breast cancer: the role of the microbiota and microbial metabolites in the tumor microenvironment.Gut microbes · 2026Review
- Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.Gut microbes · 2026Article
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome.Gut microbes · 2026Review
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients.Gut microbes · 2026Article
- Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: mechanisms, therapeutic strategies, and clinical perspectives.Gut microbes · 2026Review
- The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors.Gut microbes · 2026Review
- Alteration of gut microbiota contributes to peritoneal fibrosis through increased production of trimethylamine N-oxide.Gut microbes · 2026Article
3,383 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
48 authors at 10 institutions in 3 countries.
Bertrand RoutyGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0002-0756-6571
Emmanuelle Le ChatelierMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.ORCID http://orcid.org/0000-0002-2724-0536
Lisa DerosaGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Connie P M DuongGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0002-9067-8557
Maryam Tidjani AlouGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Romain DaillèreGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0003-3617-6377
Aurélie FluckigerGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0001-7135-0049
Meriem MessaoudeneGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Conrad RauberGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Maria P RobertiGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Marine FidelleGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Caroline FlamentGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Vichnou Poirier-ColameGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Paule OpolonGustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, France.
Christophe KleinCentre de Recherche des Cordeliers, INSERM, Université Paris Descartes, Sorbonne Paris Cité, UMRS 1138, Université Pierre et Marie Curie Université Paris 06, Sorbonne Universités, Paris, France.
Kristina IribarrenMetabolomics and Cell Biology Platforms, GRCC, Villejuif, France.ORCID http://orcid.org/0000-0002-2930-8573
Laura MondragónMetabolomics and Cell Biology Platforms, GRCC, Villejuif, France.ORCID http://orcid.org/0000-0002-3257-045X
Nicolas JacquelotGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0003-0282-1892
Bo QuGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0001-7947-3350
Gladys FerrereGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Céline ClémensonGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Laura MezquitaGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Jordi Remon MasipGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0001-9839-149X
Charles NaltetThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
Solenn BrosseauThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.
Coureche KaderbhaiDepartment of Medical Oncology, Center GF Leclerc, Dijon, France.
Corentin RichardDepartment of Medical Oncology, Center GF Leclerc, Dijon, France.
Hira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Florence LevenezMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
Nathalie GalleronMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
Benoit QuinquisMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.
Nicolas PonsMGP MetaGénoPolis, INRA, Université Paris-Saclay, Jouy-en-Josas, France.ORCID http://orcid.org/0000-0003-1926-8077
Bernhard RyffelMolecular Immunology and Embryology, UMR 7355, CNRS, University of Orleans, Orléans, France.
Véronique Minard-ColinGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Patrick GoninGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0001-6151-4580
Jean-Charles SoriaGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Eric DeutschGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0002-8223-3697
Yohann LoriotGustave Roussy Cancer Campus (GRCC), Villejuif, France.
François GhiringhelliDepartment of Medical Oncology, Center GF Leclerc, Dijon, France.
Gérard ZalcmanThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Hospital Bichat-Claude Bernard, AP-HP, Université Paris-Diderot, Paris, France.ORCID http://orcid.org/0000-0002-0343-9575
François GoldwasserParis Descartes University, Sorbonne Paris Cité, Paris, France.
Bernard EscudierGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0002-4626-0479
Matthew D HellmannDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2670-9777
Alexander EggermontGustave Roussy Cancer Campus (GRCC), Villejuif, France.ORCID http://orcid.org/0000-0001-7458-4326
Didier RaoultURMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU-Méditerranée Infection, 13005 Marseille, France.
Laurence AlbigesGustave Roussy Cancer Campus (GRCC), Villejuif, France.
Guido KroemerMetabolomics and Cell Biology Platforms, GRCC, Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.ORCID http://orcid.org/0000-0002-9334-4405
Laurence ZitvogelGustave Roussy Cancer Campus (GRCC), Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.ORCID http://orcid.org/0000-0003-1596-0998
Université Paris-Sud · FRInserm · FRInstitut Gustave Roussy · FRDélégation Paris 5 · FRUniversité Paris-Saclay · FRCentre Georges François Leclerc · FRUniversité Claude Bernard Lyon 1 · FRMemorial Sloan Kettering Cancer Center · USCentre National de la Recherche Scientifique · FRUniversité d'Orléans · FR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MAbstract
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlations between clinical responses to ICIs and the relative abundance of
Indexed as
Fecal Microbiota TransplantationAnimalsAnti-Bacterial AgentsAntibodies, MonoclonalCD4 AntigensFecesGastrointestinal MicrobiomeHumansImmunotherapyInterleukin-12MetagenomeMiceNeoplasmsProgrammed Cell Death 1 ReceptorReceptors, CCRReceptors, CXCR3Anti-Bacterial AgentsAntibodies, MonoclonalCC chemokine receptor 9CD4 AntigensInterleukin-12Programmed Cell Death 1 ReceptorReceptors, CCRReceptors, CXCR3
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03817125ClinicalTrials.gov
NCT04204434ClinicalTrials.gov
NCT04262687ClinicalTrials.gov
NCT05119010ClinicalTrials.gov
NCT05163106ClinicalTrials.gov
NCT05620004ClinicalTrials.gov
and 1 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.